

Prior Authorization Request Form Fax Back To: (866) 940-7328 Phone: (800) 310-6826

## **Specialty Medication Prior Authorization Cover Sheet**

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to <a href="https://www.uhcprovider.com">www.uhcprovider.com</a> for medication fax request forms.)

Patient Information					
Patient's Name:					
Insurance ID:	Date of Birth:	Height: Weight:			
Address:		Apartment #:			
City:	State:	Zip Code:			
Phone Number:	Alternate Phone:	Sex: ☐ Male ☐ Fem	ale		
Provider Information					
Provider's Name:	Provider ID Number:				
Address:	City:	State: Zip Code:			
Suite Number:	Building Number:				
Phone Number:	Fax number:				
Provider's Specialty:					
Medication Information					
Medication:	Quantity:	ICD10 Code:			
Directions:	Diagnosis:	Refills:			
Physician Signature**:		Initial here if DAW:			
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.					
Medication Instructions					
Medication Instructions  Has the patient been instructed on how to Self-A	Administer?	☐ Yes ☐ No			
	Administer?	☐ Yes ☐ No			
Has the patient been instructed on how to Self-					
Has the patient been instructed on how to Self- Is this medication a New Start?	Initiation Date: / /	☐ Yes ☐ No			
Has the patient been instructed on how to Self-Alls this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reserved:  **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No  Date of Last Dose: / /  ☐ Yes ☐ No  pport stated diagnosis.	n(s)		
Has the patient been instructed on how to Self-Alls this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical research any pertinent clinical informational clinical information may be needed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No  Date of Last Dose: / /  ☐ Yes ☐ No  pport stated diagnosis.	n(s)		
Has the patient been instructed on how to Self-Alls this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reserved:  **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to sued depending on your patient ian Signature" above and comformation"	☐ Yes ☐ No  Date of Last Dose: / /  ☐ Yes ☐ No  pport stated diagnosis. s plan, including medication  plete	n(s)		
Has the patient been instructed on how to Self-Alls this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reservity the self-Alls and pertinent clinical informational clinical information may be needed previously tried and failed.  Delivery Instructions  Note: Delivery coordination requires a "Physical "Provider Information" and "Patient Information" and "Patient Information" and "Patient Information"	Initiation Date: / / sponse to current therapy? Ation that would pertain to sued depending on your patient ian Signature" above and comformation" ided free of charge to the patient	☐ Yes ☐ No  Date of Last Dose: / / ☐ Yes ☐ No  pport stated diagnosis. s plan, including medication  plete  at at the time of delivery	n(s)		



## Nerlynx - Washington

## PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

On attended Manufacture Inform		iow at iea	ist 24 Hours for	review.				
Section A – Member Information First Name:	nation	Last Name:			Member ID:			
Address:		l						
City:		State:			ZIP Code:			
Phone:		DOB:			Allerg	ies:		
Primary Insurance Information:								
Is the requested medicatio								
Is this patient currently ho	-	Yes □ No	If recently discha	arged, list disch	narge	date:		
Section B - Provider Inform	nation						14.5./5.6	
First Name:			Last Name:				M.D./D.O.	
Address:			City:		State		ZIP code:	
Phone:	Fax:		NPI #:		Spec	ialty:		
Office Contact Name / Fax a	attention to:							
Section C - Medical Inform	ation							
Medication:					St	rength:		
Directions for use:					Q	uantity:		
Diagnosis (Please be specific & provide as much information as possible):  ICD-10 CODE:						E:		
Is this member pregnant?		If yes	, what is this men	nber's due date	?			
Section D – Previous Medi		n créh	Directions	Dates of The	. KO IN I	Pesse	n for foilure /	
Medications	Stre	ngth	Directions	Dates of Therapy Reason for failure discontinuation				
Section E – Additional infor			of why preferred r					
Please refer to	o trie patierit s	PDL at ww	w.uncprovider.co	oni for a list of p	reiem	eu aileina	lives	



Physician Signature: \_

telecopy in error, please notify the sender immediately.

## **Nerlynx - Washington**

PRIOR AUTHORIZATION REQUEST FORM

Member Firs	t name:	Member Last name:	Member DOB:					
Clinical and Drug Specific Information								
ALL REQUESTS								
	Does the patient have anyone of the following diagnoses? (If yes, check which applies)							
□ Yes □ No								
	□ Breast cancer without metastases							
□ Yes □ No	Is the disease human epidermal growth factor receptor (HER2)-positive?							
□ Yes □ No	Has the patient received adjuvant trastuzumab (Herceptin) treatment? (If yes, complete section D above)							
□ Yes □ No	Has the patient already received 12 months of therapy with Nerlynx?							
□ Yes □ No	Is the use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium?  If yes, list supported use:							
		BREAST CANCER WITH MI	ETASTASES					
□ Yes □ No	Will this be used in combination with any of the following? (If yes, check which applies)  □ Xeloda (capecitabine)  □ Paclitaxel							
CONTINUATION OF THERAPY								
□ Yes □ No	Does the patient show evidence of progressive disease while on Nerlynx therapy?							
□ Yes □ No	Is there documentation of positive clinical response to Nerlynx therapy?  If yes, list response:							

**Confidentiality Notice:** This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this